PDF(Pubmed)
Abstract：
UNASSIGNED: Parkinson\'s disease (PD) is an incurable, progressive, neurodegenerative disorder. As PD advances and symptoms progress, patients become increasingly dependent on family and carers. Traditional cost-effectiveness analyses (CEA) only consider patient and payer-related outcomes, failing to acknowledge impacts on families, carers, and broader society. This novel Social Return on Investment (SROI) analysis aimed to evaluate the broader impact created by improving access to levodopa (LD) device-aided therapies (DATs) for people living with advanced PD (aPD) in Australia.
UNASSIGNED: A forecast SROI analysis over a three-year time horizon was conducted. People living with aPD and their families were recruited for qualitative interviews or a quantitative survey. Secondary research and clinical trial data was used to supplement the primary research. Outcomes were valued and assessed in a SROI value map in Microsoft Excel™. Financial proxies were assigned to each final outcome based on willingness-to-pay, economic valuation, and replacement value. Treatment cost inputs were sourced from Pharmaceutical Benefits Schedule (PBS) and Medicare Benefits Scheme (MBS) published prices.
UNASSIGNED: Twenty-four interviews were conducted, and 55 survey responses were received. For every $1 invested in access to LD-based DATs in Australia, an estimated $1.79 of social value is created. Over 3 years, it was estimated $277.16 million will be invested and $406.77 million of social return will be created. This value is shared between people living with aPD (27%), their partners (22%), children (36%), and the Australian Government (15%). Most of the value created is social and emotional in nature, including reduced worry, increased connection to family and friends, and increased hope for the future.
UNASSIGNED: Investment in LD-based DATs is expected to generate a positive social return. Over 50% of the value is created for the partners and children of people living with aPD. This value would not be captured in traditional CEA. The SROI methodology highlights the importance of investing in aPD treatment, capturing the social value created by improved access to LD-based DATs.
UNASSIGNED: A forecast SROI analysis over a three-year time horizon was conducted. People living with aPD and their families were recruited for qualitative interviews or a quantitative survey. Secondary research and clinical trial data was used to supplement the primary research. Outcomes were valued and assessed in a SROI value map in Microsoft Excel™. Financial proxies were assigned to each final outcome based on willingness-to-pay, economic valuation, and replacement value. Treatment cost inputs were sourced from Pharmaceutical Benefits Schedule (PBS) and Medicare Benefits Scheme (MBS) published prices.
UNASSIGNED: Twenty-four interviews were conducted, and 55 survey responses were received. For every $1 invested in access to LD-based DATs in Australia, an estimated $1.79 of social value is created. Over 3 years, it was estimated $277.16 million will be invested and $406.77 million of social return will be created. This value is shared between people living with aPD (27%), their partners (22%), children (36%), and the Australian Government (15%). Most of the value created is social and emotional in nature, including reduced worry, increased connection to family and friends, and increased hope for the future.
UNASSIGNED: Investment in LD-based DATs is expected to generate a positive social return. Over 50% of the value is created for the partners and children of people living with aPD. This value would not be captured in traditional CEA. The SROI methodology highlights the importance of investing in aPD treatment, capturing the social value created by improved access to LD-based DATs.
摘要：
■帕金森病（PD）是一种无法治愈的疾病，进步,神经退行性疾病。随着PD的进展和症状的进展，患者越来越依赖家庭和照顾者。传统的成本效益分析(CEA)只考虑患者和付款人相关的结果，不承认对家庭的影响，看护者,更广泛的社会。这项新颖的社会投资回报率（SROI）分析旨在评估通过改善澳大利亚晚期PD（aPD）患者获得左旋多巴（LD）设备辅助疗法（DAT）所产生的更广泛影响。
■进行了为期三年的SROI预测分析。与aPD生活在一起的人及其家人被招募进行定性访谈或定量调查。次要研究和临床试验数据用于补充主要研究。结果在MicrosoftExcel™的SROI值图中进行评估和评估。根据支付意愿将财务代理分配给每个最终结果，经济估值，和重置价值。治疗成本投入来自药物福利计划(PBS)和医疗保险福利计划(MBS)公布的价格。
■进行了24次访谈，共收到55份调查回复。在澳大利亚，每投资1美元用于访问基于LD的DAT，估计创造了1.79美元的社会价值。超过3年,估计将投资277.16亿美元，创造4.0677亿美元的社会回报。这个值由与APD一起生活的人共享（27％），他们的合作伙伴（22％），儿童（36%），澳大利亚政府（15%）。创造的大部分价值本质上是社会和情感的，包括减少忧虑,增加与家人和朋友的联系，增加了对未来的希望。
■对基于LD的DAT的投资有望产生积极的社会回报。超过50％的价值是为与aPD一起生活的人的合作伙伴和子女创造的。在传统的CEA中不会捕获该值。SROI方法强调了投资于aPD治疗的重要性，捕捉通过改进对基于LD的数据的访问而创造的社会价值。
■进行了为期三年的SROI预测分析。与aPD生活在一起的人及其家人被招募进行定性访谈或定量调查。次要研究和临床试验数据用于补充主要研究。结果在MicrosoftExcel™的SROI值图中进行评估和评估。根据支付意愿将财务代理分配给每个最终结果，经济估值，和重置价值。治疗成本投入来自药物福利计划(PBS)和医疗保险福利计划(MBS)公布的价格。
■进行了24次访谈，共收到55份调查回复。在澳大利亚，每投资1美元用于访问基于LD的DAT，估计创造了1.79美元的社会价值。超过3年,估计将投资277.16亿美元，创造4.0677亿美元的社会回报。这个值由与APD一起生活的人共享（27％），他们的合作伙伴（22％），儿童（36%），澳大利亚政府（15%）。创造的大部分价值本质上是社会和情感的，包括减少忧虑,增加与家人和朋友的联系，增加了对未来的希望。
■对基于LD的DAT的投资有望产生积极的社会回报。超过50％的价值是为与aPD一起生活的人的合作伙伴和子女创造的。在传统的CEA中不会捕获该值。SROI方法强调了投资于aPD治疗的重要性，捕捉通过改进对基于LD的数据的访问而创造的社会价值。
